vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.6M, roughly 1.1× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 75.7%, a 175.0% gap on every dollar of revenue.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SPRO vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $13.7M |
| Net Profit | $31.5M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | — | -86.5% |
| Net Margin | 250.7% | 75.7% |
| Revenue YoY | 24080.8% | — |
| Net Profit YoY | 250.9% | 179.1% |
| EPS (diluted) | $0.56 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $13.7M | ||
| Q3 25 | $0 | $19.1M | ||
| Q2 25 | $0 | $8.1M | ||
| Q1 25 | $12.0K | $2.9M | ||
| Q4 24 | $52.0K | — | ||
| Q3 24 | $65.0K | — | ||
| Q2 24 | $114.0K | — | ||
| Q1 24 | $140.0K | — |
| Q4 25 | $31.5M | $10.4M | ||
| Q3 25 | $-7.4M | $-16.3M | ||
| Q2 25 | $-1.7M | $-15.8M | ||
| Q1 25 | $-13.9M | $-13.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.1M | — | ||
| Q2 24 | $-17.9M | — | ||
| Q1 24 | $-12.7M | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | -122758.3% | -472.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -28604.6% | — | ||
| Q2 24 | -16720.2% | — | ||
| Q1 24 | -9987.1% | — |
| Q4 25 | 250.7% | 75.7% | ||
| Q3 25 | — | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | -115550.0% | -452.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -26380.0% | — | ||
| Q2 24 | -15668.4% | — | ||
| Q1 24 | -9049.3% | — |
| Q4 25 | $0.56 | $-3.74 | ||
| Q3 25 | $-0.13 | $-0.11 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $-0.25 | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.32 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $35.3M |
| Total Assets | $68.9M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | $137.5M | ||
| Q3 25 | $48.6M | $103.8M | ||
| Q2 25 | $31.2M | $121.6M | ||
| Q1 25 | $48.9M | $89.1M | ||
| Q4 24 | $52.9M | — | ||
| Q3 24 | $76.3M | — | ||
| Q2 24 | $63.5M | — | ||
| Q1 24 | $82.3M | — |
| Q4 25 | $59.0M | $35.3M | ||
| Q3 25 | $26.5M | $-8.1M | ||
| Q2 25 | $32.8M | $7.1M | ||
| Q1 25 | $33.8M | $10.7M | ||
| Q4 24 | $46.1M | — | ||
| Q3 24 | $65.5M | — | ||
| Q2 24 | $80.5M | — | ||
| Q1 24 | $96.2M | — |
| Q4 25 | $68.9M | $154.7M | ||
| Q3 25 | $54.2M | $133.7M | ||
| Q2 25 | $62.1M | $133.8M | ||
| Q1 25 | $77.7M | $103.7M | ||
| Q4 24 | $110.5M | — | ||
| Q3 24 | $135.2M | — | ||
| Q2 24 | $149.9M | — | ||
| Q1 24 | $167.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | -0.26× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $-2.0M | ||
| Q3 25 | $17.4M | $-17.5M | ||
| Q2 25 | $-17.7M | $-14.5M | ||
| Q1 25 | $-4.0M | $29.0M | ||
| Q4 24 | $-23.4M | — | ||
| Q3 24 | $12.8M | — | ||
| Q2 24 | $-18.7M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.26× | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
